FDA Approves Leucovorin for Rare Condition, Not Autism Treatment

The FDA has updated the label for leucovorin, a high-dose B vitamin, to approve its use for treating cerebral folate deficiency linked to the receptor 1 gene, a condition affecting approximately 1 in 1 million people. This decision comes despite earlier claims from health officials, including FDA Commissioner Dr. Marty Makary, suggesting the drug could benefit many children with autism. The approval is significant for those with the rare genetic condition, but it has left many parents of autistic children feeling disheartened, as they had hoped for broader access to the medication. Following the September announcement, prescriptions for leucovorin surged, leading to shortages and difficulties in obtaining the drug. Parents are concerned about the future availability and insurance coverage for their children.

Key Details: • Leucovorin is now approved for cerebral folate deficiency in the receptor 1 gene. • Fewer than 50 cases of this condition have been identified worldwide. • Prescriptions for leucovorin doubled after the September briefing, causing shortages. • Parents are encouraged to discuss ongoing prescriptions with their healthcare providers.